Clinical Trial: Low-dose Bevacizumab With HSRT vs BVZ Alone for GBM at First Recurrence
Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Condition:
Glioma
Recurrent Glioma
Study Type: Interventional
Official Title: A Randomized Phase II Trial of Concurrent Low-dose Bevacizumab and HSRT Versus Bevacizumab Alone for Glioblastoma at First Recurrence: HSCK-005
Brief Summary:
This randomized phase II trial studies how well lose dose bevacizumab with Hypofractionated Stereotactic Radiotherapy (HSRT) works versus bevacizumab alone in treating patients with glioblastoma at first recurrence. The primary endpoint is 6-month progress-free survivaloverall survival after the treatment. Secondary endpoints included overall survival, objective response rate, cognitive function, quality of life and toxicity.
Read more